Munziq

Myocardial protective effects of Munziq in myocardial ischemia-reperfusion injury rats with abnormal savda syndrome

M. Abudunaibi, Mulati, A., Aisikaer, S., Zulifeiya, M., Qiao, J., Gulibositan, M., Aili, A., and Halmurat, U., “Myocardial protective effects of Munziq in myocardial ischemia-reperfusion injury rats with abnormal savda syndrome”, vol. 14, pp. 3426-3435, 2015.

This study evaluated the influence and mechanism of different Munziq doses on myocardial ischemia reperfusion injury (MIRI) rats with abnormal savda. Wistar rats (N = 96) were divided into the following 8 groups (12 rats each): ischemia-reperfusion (I/R) model group, high-dose, medium-dose, and low-dose Munziq groups, normal I/R group, sham model group, normal sham group, and Atorvastatin group. Changes in heart physiology and myocardial morphology after injury with MIRI were monitored in each group.

Effects of different doses of Savda Munziq on myocardial ischemia-reperfusion injury in rats with abnormal Savda syndrome

A. Maimaitiaili, Shabiti, A., Abudureheman, M., Musha, Z., Jun, Q., Maimaitiaili, G., Aibibula, A., and Upur, H., “Effects of different doses of Savda Munziq on myocardial ischemia-reperfusion injury in rats with abnormal Savda syndrome”, vol. 13, pp. 4729-4735, 2014.

To investigate the effects of different doses of abnormal Savda Munziq on myocardial ischemia-reperfusion injury (MI/RI) in rats with the abnormal Savda syndrome, 50 abnormal Savda animal models were randomly divided into a control group, a model group, a high-dose group, a middle-dose group, and a low-dose group, with each group containing 10 rats. The enzyme-linked immunosorbent assay was used to detect the serum myocardial enzyme and troponin levels, and hematoxylin and eosin (HE) staining was used to observe changes of the myocardial tissues in the different groups.

Subscribe to Munziq